Amino Acid, Peptide, or Protein
Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis
Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.
Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development
Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.
Novel Monthly Hemophilia A Treatment by Novos Poses Challenge to Roche’s Hemlibra
Hemophilia A, Novos, Roche, Hemlibra, monthly treatment, performance, challenge.
Moderna’s Diversification Strategy Hindered by FDA Delay in RSV Vaccine Review
Moderna, FDA, RSV vaccine, diversification strategy, vaccine review, delay
Moderna’s RSV Vaccine Decision Postponed by FDA to Late May
FDA, Moderna, RSV vaccine, decision, delay, May
MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial
MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody
Keytruda Fails to Show Significant Benefit in Newly Diagnosed Endometrial Cancer Patients
Keytruda, endometrial cancer, clinical trial, newly diagnosed, immunotherapy, treatment, cancer therapy, clinical outcomes.
Evaluation of Keytruda Combined with Chemotherapy as Post-Surgical Treatment in Newly Diagnosed Endometrial Cancer Shows Limited Efficacy
Keytruda, Merck, endometrial cancer, post-surgical therapy, newly diagnosed, chemotherapy, clinical trial, limited efficacy.
Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits
CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.